BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27107570)

  • 1. Prognostic impact of breast cancer subtypes in elderly patients.
    Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer brain metastases - A 12 year review of treatment outcomes.
    De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
    Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
    Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
    BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of small T1a/b breast cancer by tumor subtype.
    Ignatov T; Eggemann H; Burger E; Costa SD; Ignatov A
    Breast Cancer Res Treat; 2017 May; 163(1):111-118. PubMed ID: 28233107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast carcinoma subtypes show different patterns of metastatic behavior.
    Molnár IA; Molnár BÁ; Vízkeleti L; Fekete K; Tamás J; Deák P; Szundi C; Székely B; Moldvay J; Vári-Kakas S; Szász MA; Ács B; Kulka J; Tőkés AM
    Virchows Arch; 2017 Mar; 470(3):275-283. PubMed ID: 28101678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
    PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic breast cancer subtypes and central nervous system metastases.
    Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
    Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Kim JS; Kim K; Jung W; Shin KH; Im SA; Kim HJ; Kim YB; Chang JS; Kim JH; Choi DH; Park YH; Kim DY; Kim TH; Choi BO; Lee SW; Kim S; Kwon J; Kang KM; Chung WK; Kim KS; Yoon WS; Kim JH; Cha J; Oh YK; Kim IA
    Breast Cancer Res Treat; 2021 Apr; 186(2):453-462. PubMed ID: 33392845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.